Do proton pump inhibitors influence SARS-CoV-2 related outcomes? A meta-analysis
Gut
.
2021 Sep;70(9):1806-1808.
doi: 10.1136/gutjnl-2020-323366.
Epub 2020 Nov 10.
Authors
Guo-Fu Li
1
2
,
Xiao-Xiao An
2
3
,
Yichao Yu
4
,
Li-Rong Jiao
2
3
,
Daniele Canarutto
5
,
Guo Yu
6
2
,
Guangji Wang
7
,
Dan-Na Wu
8
,
Yin Xiao
9
Affiliations
1
Clinical Medical College, Yangzhou University, Yangzhou, China.
2
Institution of Drug Clinical Trial, Subei People's Hospital, Yangzhou, China.
3
College of Pharmacy, Dalian Medical University, Dalian, Liaoning, China.
4
Department of Pharmaceutics, University of Florida, Gainesville, Florida, USA.
5
Faculty of Medicine and Surgery, Vita Salute San Raffaele University, Milan, Italy.
6
Clinical Medical College, Yangzhou University, Yangzhou, China
[email protected]
.
7
Key Laboratory of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing, China.
8
Department of Pharmacy, Hainan General Hospital (Hainan Affiliated Hospital of Hainan Medical University), Haikou, China.
9
Department of Pharmacy, Haikou Affiliated Hospital of Central South University Xiangya School of Medicine, Haikou, China.
PMID:
33172925
PMCID:
PMC8355875
DOI:
10.1136/gutjnl-2020-323366
No abstract available
Keywords:
acid secretion; gastric acid; gastroesophageal reflux disease.
Publication types
Letter
Comment
MeSH terms
COVID-19*
Gastroesophageal Reflux*
Humans
Proton Pump Inhibitors / adverse effects
SARS-CoV-2
Substances
Proton Pump Inhibitors